John Barbieri Talks Lab Monitoring Challenges and Alternative Approaches for Accutane in Acne Care | AAD 2024
John Barbieri, M.D., MBA, associate professor of Harvard Medical School, spoke with Managed Healthcare Executive at this year's American Academy of Dermatology Meeting in San Diego.
Barbieri discussed the significance of Accutane (isotretinoin) in managing severe or scarring acne and focused on the concerns surrounding lab monitoring, particularly liver enzyme and lipid testing.
Barbieri presented research at the meeting that suggests liver function testing may not provide meaningful insights, and lipid testing's value in preventing pancreatitis is questioned.
He highlighted the psychological, medical and financial costs associated with monitoring and discussed alternative approaches, suggesting limited monitoring based on baseline and peak dose labs.
Additionally, he mentioned the evolving standards, with some dermatologists still practicing monthly lab monitoring.
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, according to study findings presented at the 2025 American Academy of Dermatology annual meeting.
Read More
Makeup and Skin Care Products Contain 'Forever Chemicals' | AAD 2025
March 10th 2025More than 200 products from 28 makeup, sunscreen, and shaving cream brands contained Teflon and other forever chemicals, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
March 10th 2025The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic dermatitis, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
